Answers are grounded in this paper and cite their sources.
Examines eicosanoid production in RAW264.7 cells, suggesting distinct pathways for TLR and calcium stimulation.
Arachidonic acid is released by phospholipase A2 and converted into hundreds of distinct bioactive mediators by a variety of cyclooxygenases (COX), lipoxygenases (LO), and cytochrome P450s. Because of the size and diversity of the eicosanoid class of signaling molecules produced, a thorough and systematic investigation of these biological processes requires the simultaneous quantitation of a large number of eicosanoids in a single analysis. We have developed a robust liquid chromatography/tandem mass spectrometry method that can identify and quantitate over 60 different eicosanoids in a single analysis, and we applied it to agonist-stimulated RAW264.7 murine macrophages. Fifteen different eicosanoids produced through COX and 5-LO were detected either intracellularly or in the media following stimulation with 16 different agonists of Toll-like receptors (TLR), G protein-coupled receptors, and purinergic receptors. No significant differences in the COX metabolite profiles were detected using the different agonists; however, we determined that only agonists creating a sustained Ca2+ influx were capable of activating the 5-LO pathway in these cells. Synergy between Ca2+ and TLR pathways was detected and discovered to be independent of NF-κB-induced protein synthesis. This demonstrates that TLR induction of protein synthesis and priming for enhanced phospholipase A2-mediated eicosanoid production work through two distinct pathways. Arachidonic acid is released by phospholipase A2 and converted into hundreds of distinct bioactive mediators by a variety of cyclooxygenases (COX), lipoxygenases (LO), and cytochrome P450s. Because of the size and diversity of the eicosanoid class of signaling molecules produced, a thorough and systematic investigation of these biological processes requires the simultaneous quantitation of a large number of eicosanoids in a single analysis. We have developed a robust liquid chromatography/tandem mass spectrometry method that can identify and quantitate over 60 different eicosanoids in a single analysis, and we applied it to agonist-stimulated RAW264.7 murine macrophages. Fifteen different eicosanoids produced through COX and 5-LO were detected either intracellularly or in the media following stimulation with 16 different agonists of Toll-like receptors (TLR), G protein-coupled receptors, and purinergic receptors. No significant differences in the COX metabolite profiles were detected using the different agonists; however, we determined that only agonists creating a sustained Ca2+ influx were capable of activating the 5-LO pathway in these cells. Synergy between Ca2+ and TLR pathways was detected and discovered to be independent of NF-κB-induced protein synthesis. This demonstrates that TLR induction of protein synthesis and priming for enhanced phospholipase A2-mediated eicosanoid production work through two distinct pathways. Arachidonic acid (AA) 2The abbreviations used are: AA, arachidonic acid; ActD, actinomycin D; BAY, BAY 11-7082; C1P, ceramide 1-phosphate; CHX, cycloheximide; COX, cyclooxygenase; ESI, electrospray ionization; FLAP, 5-LO activating protein; FSL-1, S-(2,3-bispalmitoyloxypropyl)-Cys-Gly-Asp-Pro-Lys-His-Pro-Ser-Phe; GC, gas chromatography; GPCR, G protein-coupled receptor; HETE, hydroxyeicosatetraenoic acid; HKLM, heat-killed Listeria monocytogenes; LC, liquid chromatography; LO, lipoxygenase; 11t LTC4, 11-trans-leukotriene C4; LT, leukotriene; LTA, lipoteichoic acid Staphylococcus aureus; LTC4, leukotriene C4; MRM, multiple reaction monitoring; MS, mass spectrometry; MS/MS, tandem MS; NF-κB, nuclear factor-κB; ODN1826, synthetic oligodeoxynucleotide 1826; PAF, platelet-activating factor; Pam3SCK4, N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R,2S)-propyl]-Cys-[S]-Ser-[S]-Lys(4) trihydrochloride; PG, prostaglandin; 15d PGD2, 15-deoxy-Δ12,14-PGD2; dhk PGD2, 13,14-dihydro-15-keto PGD2; dhk PGE2, 13,14-dihydro-15-keto PGE2; dhk PGF2α, 13,14-dihydro-15-keto PGF2α; 15d PGJ2, 15-deoxy-Δ12,14-PGJ2; PIP2, phosphatidylinositol 4,5-bisphosphate; PLA2, phospholipase; cPLA2, group IVA cytosolic PLA2; p-cPLA2 (Ser-505), cPLA2 phosphorylated at serine 505; poly(I-C), polyinosine-polycytidylic acid; TLR, Toll-like receptor; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; LPS, lipopolysaccharide; PBS, phosphate-buffered saline; HRP, horseradish peroxidase; Kdo, 3-deoxy-d-manno-2-octulosonic acid; PPAR, peroxisome proliferator-activated receptor. 2The abbreviations used are: AA, arachidonic acid; ActD, actinomycin D; BAY, BAY 11-7082; C1P, ceramide 1-phosphate; CHX, cycloheximide; COX, cyclooxygenase; ESI, electrospray ionization; FLAP, 5-LO activating protein; FSL-1, S-(2,3-bispalmitoyloxypropyl)-Cys-Gly-Asp-Pro-Lys-His-Pro-Ser-Phe; GC, gas chromatography; GPCR, G protein-coupled receptor; HETE, hydroxyeicosatetraenoic acid; HKLM, heat-killed Listeria monocytogenes; LC, liquid chromatography; LO, lipoxygenase; 11t LTC4, 11-trans-leukotriene C4; LT, leukotriene; LTA, lipoteichoic acid Staphylococcus aureus; LTC4, leukotriene C4; MRM, multiple reaction monitoring; MS, mass spectrometry; MS/MS, tandem MS; NF-κB, nuclear factor-κB; ODN1826, synthetic oligodeoxynucleotide 1826; PAF, platelet-activating factor; Pam3SCK4, N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R,2S)-propyl]-Cys-[S]-Ser-[S]-Lys(4) trihydrochloride; PG, prostaglandin; 15d PGD2, 15-deoxy-Δ12,14-PGD2; dhk PGD2, 13,14-dihydro-15-keto PGD2; dhk PGE2, 13,14-dihydro-15-keto PGE2; dhk PGF2α, 13,14-dihydro-15-keto PGF2α; 15d PGJ2, 15-deoxy-Δ12,14-PGJ2; PIP2, phosphatidylinositol 4,5-bisphosphate; PLA2, phospholipase; cPLA2, group IVA cytosolic PLA2; p-cPLA2 (Ser-505), cPLA2 phosphorylated at serine 505; poly(I-C), polyinosine-polycytidylic acid; TLR, Toll-like receptor; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; LPS, lipopolysaccharide; PBS, phosphate-buffered saline; HRP, horseradish peroxidase; Kdo, 3-deoxy-d-manno-2-octulosonic acid; PPAR, peroxisome proliferator-activated receptor. and its eicosanoid metabolites are associated with a variety of different physiological systems, including the central nervous, cardiovascular, gastrointestinal, genitourinary, respiratory, and immune systems. Eicosanoids are formed when phospholipase A2 (PLA2) action liberates AA from the sn-2 position of membrane phospholipids (1Six D.A. Dennis E.A. Biochim. Biophys. Acta. 2000; 1488: 1-19Crossref PubMed Scopus (1215) Google Scholar, 2Schaloske R.H. Dennis E.A. Biochim. Biophys. Acta. 2006; 1761: 1246-1259Crossref PubMed Scopus (723) Google Scholar). Free AA is then converted into potent bioactive mediators by the action of the various cyclooxygenases (COX), lipoxygenases (LO), and cytochrome P450s. The eicosanoid production cascade often works in a nonlinear fashion, with multiple enzymes creating a single product and multiple products acting as a substrate for a single enzyme. COX activity produces prostaglandins (PG) and hydroxyeicosatetraenoic acids (HETEs) (3Simmons D.L. Botting R.M. Hla T. Pharmacol. Rev. 2004; 56: 387-437Crossref PubMed Scopus (1337) Google Scholar, 4Smith W.L. DeWitt D.L. Garavito R.M. Annu. Rev. Biochem. 2000; 69: 145-182Crossref PubMed Scopus (2449) Google Scholar), lipoxygenases can and 69: PubMed Scopus Google Scholar, Scopus Google Scholar, Google Scholar, PubMed Scopus Google Scholar). the production of and as as of various eicosanoids PubMed Scopus Google Scholar). enzymes can eicosanoids by and T. T. PubMed Scopus Google Scholar). enzymes and biological receptors are various and signaling PubMed Scopus Google Scholar). This is by and 2006; PubMed Scopus Google Scholar), that to the of of eicosanoid and Google Scholar, Biochem. PubMed Scopus Google Scholar). This method is for in the of however, and for of spectrometry were developed that these Rev. PubMed Scopus Google and the simultaneous of multiple of the method is the that eicosanoids be in to be for a variety of developed the number of eicosanoids that can be a single method is to of the eicosanoids for eicosanoids are for gas R.M. Biochem. PubMed Scopus Google Scholar), for of the The of electrospray the for by eicosanoids in biological The a eicosanoid in mass using with mass eicosanoids can be and can be to to a of distinct product of can be in a single using multiple reaction when with liquid identify a of the was in by and in Biochem. PubMed Scopus Google to quantitate eicosanoids from a biological the of was with the of to eicosanoids from T. T. T. PubMed Scopus Google Scholar). and T. T. Biochem. PubMed Scopus Google have developed a method that can and quantitate different eicosanoids from biological detected a of eicosanoids that was with a or a eicosanoids have discovered to with biological thorough investigation of these biological processes requires to a large number of eicosanoids in a single analysis. to in the we have a of for a large number of eicosanoids and have a of and that for the and quantitation of a large number of these in a single using it be to identify eicosanoid signaling and a of biological This applied to the of RAW264.7 macrophages. a number of Toll-like receptors T. PubMed Scopus Google Scholar). a of receptors that of to the induction of and eicosanoid receptors that can in Ca2+ Ca2+ a number of processes the and to group IVA cytosolic and 5-LO to the membrane (1Six D.A. Dennis E.A. Biochim. Biophys. Acta. 2000; 1488: 1-19Crossref PubMed Scopus (1215) Google Scholar, 69: PubMed Scopus Google Scholar). and through G protein-coupled receptors that a Ca2+ Dennis E.A. Biochem. PubMed Scopus Google Scholar, 2006; PubMed Scopus Google Scholar, PubMed Google Scholar). as and purinergic by of can sustained in Ca2+ that eicosanoid production Dennis E.A. Biochem. PubMed Scopus Google Scholar, PubMed Google Scholar, Dennis E.A. PubMed Scopus Google Scholar). the to Ca2+ agonists to be by priming with a of a TLR Dennis E.A. Biochem. PubMed Scopus Google Scholar, PubMed Scopus Google Scholar, Google Scholar, Dennis E.A. Biochem. PubMed Scopus Google Scholar, Dennis E.A. PubMed Google Scholar, R.H. Dennis E.A. Biochim. Biophys. Acta. PubMed Scopus Google Scholar), eicosanoid the of TLR and Ca2+ stimulation we to these of eicosanoid two distinct eicosanoid We the between TLR and Ca2+ and we have of the for priming and stimulation of eicosanoid murine were from were from were from was from and were from and were from The TLR agonists W.L. DeWitt D.L. Garavito R.M. Annu. Rev. Biochem. 2000; 69: 145-182Crossref PubMed Scopus (2449) Google heat-killed Listeria lipoteichoic acid from Staphylococcus polyinosine-polycytidylic acid from and synthetic oligodeoxynucleotide were from and was from was from PAF, and were from The cPLA2, p-cPLA2 (Ser-505), and were from The and 5-LO were from The was from The was from and BAY were from was from was a from was a from of were or and RAW264.7 murine were in with and at in a were in with of media for for and to for the media were with of media and were were for at the following were for at the following priming were with for by the of or for media were for eicosanoid the of media was and was with of and of to the of to by were for at to and then eicosanoids were in the by into of and then of and of Eicosanoids were using were with of and then of the the were with and the eicosanoids were then with of The was and in of acid for analysis. was determined that of the The of eicosanoids were with a it was determined that the of the eicosanoid of the eicosanoid were to be to media were to number using the media were the were in of and at for quantitation using the to the into for eicosanoid analysis. Because the quantitation we determined from a in these of of was determined by to and of eicosanoids was by Eicosanoids were by a at a of at The was in acid and were using a and with a from to between and was to from to and was to from to and was to by and 16 Eicosanoids were using a tandem mass multiple reaction in The electrospray was and the was of eicosanoid used as a the product the and that were used for as as the of eicosanoid was by the by and PubMed Scopus Google Scholar). and AA were as from the of and were determined by was by of eicosanoid to the following of eicosanoid and are as of eicosanoid were with and into of were determined and using the of protein was and a or the membrane was with in for with either or in with for and with for the membrane was with protein in for with of the in and with of the for were using the IVA IVA cPLA2 activity was determined by the of were as phosphatidylinositol and with acid was from the substrate acid Dennis E.A. PubMed Scopus Google Scholar, Dennis E.A. Biochem. PubMed Scopus Google and in a TLR two that the of eicosanoids in TLR and in Ca2+ TLR in the including the induction of in protein and in protein We have in eicosanoid when RAW264.7 were by to different TLR to the induction of a number of through the We by the eicosanoids released into the media of RAW264.7 when with of TLR agonists was to be and the eicosanoid the was the that the was these we eicosanoids in different were We with a with activity to that of is a LPS, of and acid The that are have and the of the a acid that is to and only the Dennis E.A. 2006; PubMed Scopus Google Scholar). we for of the different when RAW264.7 were with for only produced by the COX pathway were PGF2α, PGE2, and were and metabolites PGJ2, and were metabolites 13,14-dihydro-15-keto 13,14-dihydro-15-keto and 13,14-dihydro-15-keto were The products of COX action AA, and were was by the COX that are by the COX eicosanoids produced by RAW264.7 different in a The eicosanoid profiles of and when with the agonists for were the as that with The was that in to the dhk PGF2α, or dhk was these we of the by we to the the of the and only the eicosanoid profiles be We then and these only detected in the This of stimulation of that was the eicosanoid released as as and were of from a single and 15d were the product 15d of and produced significant of of in by only a of these agonists produced different of the eicosanoid from the by the to in eicosanoid production over the in RAW264.7 cells. Ca2+ is by Ca2+ the of as cPLA2 and to the membrane (1Six D.A. Dennis E.A. Biochim. Biophys. Acta. 2000; 1488: 1-19Crossref PubMed Scopus (1215) Google Scholar, 69: PubMed Scopus Google can eicosanoid Ca2+ can in two distinct Dennis E.A. Biochem. PubMed Scopus Google Scholar, PubMed Google Scholar). The of Ca2+ a to in the of the membrane a sustained Ca2+ from the influx of of these Ca2+ of these that Ca2+ were and and to a Ca2+ Dennis E.A. Biochem. PubMed Scopus Google Scholar, PubMed Google Scholar), and sustained in Ca2+ The of and stimulation are in a stimulation with or PGF2α, PGE2, PGD2, and were and metabolites and 15d were detected 15d and the dhk were 15d was detected it requires two a of to 60 of 15d was into dhk PGF2α, dhk PGE2, and dhk requires and a and these products were of the eicosanoids were The that the eicosanoids released in these pathways were and AA The were between for and for that Ca2+ is for and eicosanoid these were in the of The of eicosanoid was by the of using that a in activating eicosanoid production in to these two This by Dennis E.A. Biochem. PubMed Scopus Google Scholar), that the by in murine of PubMed Google Scholar), and purinergic receptors, and Dennis E.A. Biochem. PubMed Scopus Google Scholar), a Ca2+ sustained Ca2+ in the in to a Ca2+ and The of RAW264.7 by either or that these agonists were capable of eicosanoid produced by or and in the 5-LO of LTC4, and its 11t were produced of and of the stimulation produced of and LTC4, and production was by the 5-LO when was it the production of 5-LO products COX activity the of a sustained Ca2+ influx in the of that the of Ca2+ from the was for This is the of in the of TLR for to AA and as a stimulation of produced a to and PAF, of the eicosanoids produced by 15d PGJ2, dhk PGF2α, dhk PGE2, and dhk be that the at 60 a over and is of the Ca2+ it in to the in TLR and of of 16 agonists that only or significant differences in the eicosanoid of the sustained of the of these we to the eicosanoid and over between purinergic with and the with the we the of eicosanoids to the stimulation AA to at and to by AA the was produced in to at and to by and were released into the media at a over PGD2, however, then to This to be in large to in metabolites PGJ2, 15d PGD2, and 15d of were detected of 15d and 15d The of the of and its metabolites to to and and metabolites were detected intracellularly the stimulation of purinergic receptors a sustained Ca2+ influx and production of eicosanoids by RAW264.7 AA the of stimulation and to by AA was released into the media the and the and products of COX and were released of in the over the and were released of and for the of the and 15d to a with a of released in the by a the of was 11t the and then for the of the of and metabolites were detected the at by these metabolites were detected only in the Synergy between TLR and Ca2+ and Ca2+ agonists can eicosanoid production in cells. work that the of eicosanoid can be by these agonists Dennis E.A. Biochem. PubMed Scopus Google Scholar, Dennis E.A. Biochem. PubMed Scopus Google Scholar, Dennis E.A. PubMed Google Scholar, R.H. Dennis E.A. Biochim. Biophys. Acta. PubMed Scopus Google Scholar). PubMed Scopus Google Scholar, Google that the for 60 murine for enhanced eicosanoid by Ca2+ We RAW264.7 with and Ca2+ agonists to these pathways were or in activating eicosanoid identify the of between we a is the of eicosanoid produced by is the of the eicosanoid produced by the Ca2+ and Ca2+ is the of the eicosanoid produced by stimulation with the agonists independent the eicosanoid production be and the be the two agonists the and the be that that of either the be the of pathway and these agonists to eicosanoids the of the the be and a RAW264.7 were with for with a of of Ca2+ PAF, or The are in the for the in and were The only was that the was with enhanced and AA by and of these metabolites by however, was enhanced by priming by either or was the enhanced that was between the 5-LO products and the of the is to NF-κB-induced protein and to be the that for enhanced eicosanoid production Dennis E.A. PubMed Google Scholar, R.H. Dennis E.A. Biochim. Biophys. Acta. PubMed Scopus Google Scholar, 2000; PubMed Scopus Google Scholar). protein of cPLA2 and protein were by and the of stimulation The of cPLA2 phosphorylated at serine have to protein activity the 2000; PubMed Scopus Google Scholar), were for cPLA2 activity with in This activity for We a significant in the of cPLA2 activity following stimulation with either or Because the of detected by and the of cPLA2 by in it that to of the cPLA2 the of the or its This protein synthesis as a for eicosanoid production by TLR the of synthesis the was by and CHX, the and of of with BAY synthesis by in the production of protein for eicosanoid in the of the stimulation of the purinergic receptors was only by these that or protein synthesis is for the and that the are to these eicosanoid protein synthesis was for the of eicosanoid RAW264.7 were with for and with a of in the of ActD, CHX, and BAY these the eicosanoid produced by and the of protein synthesis to of leukotriene or AA of activity by BAY the between these pathways. a of was a and demonstrates of protein synthesis eicosanoid and from priming for enhanced eicosanoid in RAW264.7 a large number of distinct G protein-coupled receptors, and purinergic receptors. these receptors cPLA2 to AA from membrane phospholipids and eicosanoid by different pathways. was that by using a of a number of different eicosanoid profiles be that the of we the eicosanoid profiles of RAW264.7 with 16 different We that of the 16 agonists produced the eicosanoid This was by COX and by the eicosanoid produced was and its products PGJ2, 15d PGJ2, and 15d is with the that the of over at the 5-LO activity is by was that the agonists and the as TLR agonists a Ca2+ that eicosanoid synthesis and protein synthesis protein in agonists eicosanoid synthesis 5-LO and of these two agonists profiles as the The of the eicosanoid in to these agonists was in of the that from in different eicosanoid as by that 2006; PubMed Scopus Google Scholar, PubMed Scopus Google and in different of are T. T. Biochem. PubMed Scopus Google Scholar). a of 2004; PubMed Scopus Google that in have a of to macrophages. was to in the and The between in and the RAW264.7 is that the in different it is that the eicosanoid was to when the RAW264.7 was of the purinergic by of produced a different eicosanoid in RAW264.7 cells. to eicosanoids detected from the 5-LO pathway to the production of can the to a Ca2+ and to sustained Ca2+ PubMed Google Scholar). of the purinergic receptors, only the requires of for PubMed Scopus Google Scholar, Rev. PubMed Scopus Google Scholar). This is and in RAW264.7 and Dennis E.A. PubMed Scopus Google have that is for the of metabolite in to stimulation in murine macrophages. of in the and cytosolic and Pharmacol. 2006; PubMed Scopus Google Scholar, R.M. 2006; PubMed Scopus Google Scholar). The eicosanoid by stimulation was with is a Ca2+ that a sustained Ca2+ in murine Dennis E.A. Biochem. PubMed Scopus Google Scholar). the of 5-LO products was by of when with and the of the 5-LO products were produced in to the stimulation only the 5-LO pathway the eicosanoid This is of the Ca2+ are for 5-LO activity in cPLA2 at the membrane and to the of the these we have the eicosanoid the AA at 60 and as to The AA the was the detected the large between the of the and of the of AA be was detected the at a to the the of and Dennis E.A. PubMed Scopus Google Scholar), in following of phospholipids and stimulation of murine macrophages. of prostaglandins and metabolites were detected intracellularly were for the of a of AA that by The AA with the of and that were released in the of to AA the to AA, of and be detected intracellularly at stimulation with eicosanoid to in the that the eicosanoids in RAW264.7 are that the metabolite 15d be detected intracellularly using a T. T. PubMed Scopus Google Scholar), and that it through the We were to significant of 15d in the at that at of metabolite the 15d is to in RAW264.7 it is either or the to are that are TLR and Ca2+ have that with to for enhanced eicosanoid production in to the Ca2+ Dennis E.A. Biochem. PubMed Scopus Google Scholar, Dennis E.A. PubMed Google Scholar, R.H. Dennis E.A. Biochim. Biophys. Acta. PubMed Scopus Google Scholar). that were with to with PAF, creating enhanced of metabolites that was in the of protein synthesis and This to the that protein was for priming the for a Ca2+ cPLA2 to we TLR priming in RAW264.7 cells. the either or we have the eicosanoid with agonists and eicosanoid production that was The Ca2+ was to eicosanoid through pathway was with the the to the of eicosanoids produced by and the of significant the of AA, and 5-LO products The 5-LO product was enhanced by the AA the of AA and was enhanced This that cPLA2 AA and 5-LO products were from the work in that we of This from is in to the that in the the was the that TLR significant of of that in RAW264.7 to eicosanoid and is into is significant of the when and were used to protein or BAY was used to eicosanoid production was the the of AA were This that eicosanoid production is protein and that production requires the AA produced in to the of COX can be used by This be to the that a Ca2+ cPLA2 is to the membrane D.A. Dennis E.A. PubMed Scopus Google Scholar, D.A. Dennis E.A. PubMed Scopus Google or ceramide T. T. Biochem. Pharmacol. 2006; PubMed Scopus Google Scholar, 2004; PubMed Scopus Google Scholar), is in a Ca2+ cPLA2 to or to a different of to 60 of stimulation with in the of protein synthesis only a eicosanoid of significant eicosanoid synthesis. Because eicosanoid production was it is that protein synthesis a significant in The eicosanoid of that were with was by the of ActD, CHX, and This was in of the that these eicosanoid and eicosanoid the was by these as as by the This that priming the NF-κB-induced protein synthesis by The of eicosanoid from protein synthesis is by the in The of cPLA2, and The to be to of cPLA2 and the of AA and protein synthesis only COX Because the and in activity of cPLA2 are in the that cPLA2 to its membrane substrate are to a significant of have developed a that the eicosanoid profiles and priming in RAW264.7 This for the through the of cPLA2, COX, and The activity of cPLA2 can be by the in the be by is that for cPLA2 in PubMed Scopus Google Scholar, Biochem. PubMed Scopus Google Scholar), and in the of to in to various the activity be by of the enzyme. of to cPLA2 activity when in PubMed Scopus Google however, is is in to in the PubMed Scopus Google Scholar, Dennis E.A. Biochem. Biophys. 2000; PubMed Scopus Google Scholar). that is phosphorylated cPLA2 in RAW264.7 and the in The and for of cPLA2 is through of its to cPLA2 is a and to the membrane to its substrate and to to be by in Ca2+ and in cytosolic Ca2+ cPLA2 to phospholipids in its can be in a through in membrane and D.A. Dennis E.A. PubMed Scopus Google Scholar, D.A. Dennis E.A. PubMed Scopus Google have that cPLA2 membrane and to membrane a that activity of the enzyme. with TLR Dennis E.A. 2006; PubMed Scopus Google Scholar, 2006; PubMed Scopus Google Scholar). and T. T. Biochem. Pharmacol. 2006; PubMed Scopus Google have a in with ceramide PubMed Scopus Google Scholar, 2000; PubMed Google and D.A. Biochim. Biophys. Acta. PubMed Scopus Google have to cPLA2 membrane of a number of and the activity of the cPLA2 enzyme. The of the COX enzymes to be by is is at in can be by in to enzymes Ca2+ or for the requires a for activity that is (3Simmons D.L. Botting R.M. Hla T. Pharmacol. Rev. 2004; 56: 387-437Crossref PubMed Scopus (1337) Google Scholar, 4Smith W.L. DeWitt D.L. Garavito R.M. Annu. Rev. Biochem. 2000; 69: 145-182Crossref PubMed Scopus (2449) Google Scholar), to its a number of This production in the of to cPLA2, 5-LO to be by a of a to cPLA2 that requires significant of Ca2+ for to the This can be by (1Six D.A. Dennis E.A. Biochim. Biophys. Acta. 2000; 1488: 1-19Crossref PubMed Scopus (1215) Google Scholar, PubMed Scopus Google Scholar). the of is for in its 69: PubMed Scopus Google Scholar). The activity of 5-LO can be by produced by TLR 2000; PubMed Scopus Google Scholar). cPLA2, COX, and 5-LO we of for eicosanoid to or a of sustained is This to a of AA, as cPLA2 to the membrane in to Because or protein synthesis released AA be converted to eicosanoids by production be by the of as COX The Ca2+ are to to of and a sustained Ca2+ that to a of cPLA2 to the This is by a of metabolites by and when with to cPLA2 a sustained Ca2+ is to the COX and 5-LO pathways are and and stimulation protein synthesis that to COX in 60 Because Ca2+ it cPLA2 by by the of or that the to the the 5-LO is is Ca2+ This stimulation pathway produces a of The of eicosanoid production by either or sustained Ca2+ in to stimulation with to significant protein in it for the significant in the of or C1P, the in cPLA2 of these the significant in the of the of a Ca2+ that only the of the pathway is and the eicosanoid priming two in the RAW264.7 to the of AA the of AA and of the eicosanoids detected are are in eicosanoid including arachidonic a in cPLA2 We have that the of cPLA2 and its in activity to the protein pathways. we in cPLA2 for cPLA2 be is that the Ca2+ be acting with or to the of cPLA2 at the have that the activity of cPLA2, a for The of the is that for AA This that the 5-LO activity is enhanced as 5-LO a Ca2+ and as cPLA2, we have the for of 5-LO activity the of the AA through the 5-LO This for the of in the it is that the of COX are over the The that the and agonists with priming the that requires a sustained in Ca2+ to the synthesis of the The of with and be the COX are we have that it is to eicosanoid products when This to of the priming of RAW264.7 and to that priming a of cPLA2, and that requires protein synthesis. are to identify the of We for mass spectrometry and for the with
No takes yet. Share an insight, caveat, or question.
Buczynski et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: